日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.

用于预测高级别浆液性卵巢癌患者对铂类药物治疗的临床反应的体外 3D 微肿瘤测试平台

Koedoot Esmee, van der Meer Dieudonné J, van Altena Anne M, Ceton Lieke J, Sijsenaar Timothy J P, Montero Marta G, Grillet Fanny, Piek Jurgen M J, Bekkers Ruud L M, van der Vorst Maurice J D L, Huijben Auke M T, Baalbergen Astrid, Voogdt Kevin G J A, Verhoeven Loes, Smedts Huberdina P M, Weber Klaus, Hazelbag Hans Marten, Bosse Tjalling, van Persijn-van Meerten Els L, de Kroon Cornelis D, Price Leo, Vader Willemijn, Kroep Judith R, Ottevanger Nelleke P B

Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC.

药理学上的 CLK 抑制会破坏 SR 蛋白功能和 RNA 剪接,从而阻断 TNBC 中的细胞生长和迁移

Liu Nasi, van der Velde Jurjun J S, Ramdjielal Sherien, Koedoot Esmee, van Overbeek Nila K, Batenburg Daisy, Vertegaal Alfred C O, van de Water Bob, Le Dévédec Sylvia E

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

类器官作为转移性结直肠癌个性化治疗的生物标志物:药物筛选优化及其与患者反应的相关性

Lidwien P Smabers #, Emerens Wensink #, Carla S Verissimo, Esmee Koedoot, Katerina-Chara Pitsa, Maarten A Huismans, Celia Higuera Barón, Mayke Doorn, Liselot B Valkenburg-van Iersel, Geert A Cirkel, Anneta Brousali, René Overmeer, Miriam Koopman, Manon N Braat, Bas Penning de Vries, Sjoerd G Elias, 

One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset

四分之一的新冠肺炎患者在发病12个月后出现肺功能受损

van Willigen, Hugo D G; Wynberg, Elke; Verveen, Anouk; Dijkstra, Maartje; Verkaik, Bas J; Figaroa, Orlane J A; de Jong, Marianne C; van der Veen, Annelou L I P; Makowska, Agata; Koedoot, Nelleke; Nieuwkerk, Pythia T; Boyd, Anders; Prins, Maria; de Jong, Menno D; de Bree, Godelieve J; van den Aardweg, Joost G

A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer

激酶抑制剂筛选揭示 MEK1/2 是拮抗 ERα 阳性管腔乳腺癌中 IGF1R 介导的抗雌激素耐药性的新型治疗靶点

L Wester, S Venneker, M Hazenoot, C Pont, E Koedoot, A M Timmermans, J W M Martens, M P H M Jansen, C E M Kockx, W F J van IJcken, J H N Meerman, Y Zhang, B van de Water

Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention

剪接因子通过 SUN2 相互作用和 sororin 内含子保留控制三阴性乳腺癌细胞有丝分裂

Esmee Koedoot, Eline van Steijn, Marjolein Vermeer, Román González-Prieto, Alfred C O Vertegaal, John W M Martens, Sylvia E Le Dévédec, Bob van de Water

Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy

3D 培养中乳腺癌亚型的差异重编程及其对靶向治疗敏感性的影响

Esmee Koedoot, Liesanne Wolters, Marcel Smid, Peter Stoilov, Gerhard A Burger, Bram Herpers, Kuan Yan, Leo S Price, John W M Martens, Sylvia E Le Dévédec, Bob van de Water

Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes

揭示控制乳腺癌细胞迁移的信号通路,识别新的转移驱动基因

Esmee Koedoot, Michiel Fokkelman, Vasiliki-Maria Rogkoti, Marcel Smid, Iris van de Sandt, Hans de Bont, Chantal Pont, Janna E Klip, Steven Wink, Mieke A Timmermans, Erik A C Wiemer, Peter Stoilov, John A Foekens, Sylvia E Le Dévédec, John W M Martens, Bob van de Water

Co-regulated gene expression of splicing factors as drivers of cancer progression

剪接因子的协同调控基因表达是癌症进展的驱动因素

Koedoot, Esmee; Smid, Marcel; Foekens, John A; Martens, John W M; Le Dévédec, Sylvia E; van de Water, Bob

Splicing regulatory factors in breast cancer hallmarks and disease progression

乳腺癌特征和疾病进展中的剪接调控因子

Koedoot, Esmee; Wolters, Liesanne; van de Water, Bob; Dévédec, Sylvia E Le